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Background: Compounds of plant origin and food components have attracted scientific attention for use as
agents for cancer prevention and treatment. Wine contains polyphenols that were shown to have anti-cancer and
other health benefits. The survival pathways of Akt and extracellular signal-regulated kinase (Erk), and the tumor
suppressor p53 are key modulators of cancer cell growth and survival. In this study, we examined the effects of
wine on proliferation and survival of human Non-small cell lung cancer (NSCLC) cells and its effects on signaling
events.
Methods: Human NSCLC adenocarcinoma A549 and H1299 cells were used. Cell proliferation was assessed by
thymidine incorporation. Clonogenic assays were used to assess cell survival. Immunoblotting was used to examine
total and phosphorylated levels of Akt, Erk and p53.
Results: In A549 cells red wine inhibited cell proliferation and reduced clonogenic survival at doses as low as
0.02%. Red wine significantly reduced basal and EGF-stimulated Akt and Erk phosphorylation while it increased the
levels of total and phosphorylated p53 (Ser15). Control experiments indicated that the anti-proliferative effects of
wine were not mediated by the associated contents of ethanol or the polyphenol resveratrol and were independent of
glucose transport into cancer cells. White wine also inhibited clonogenic survival, albeit at a higher doses (0.5-2%), and
reduced Akt phosphorylation. The effects of both red and white wine on Akt phosphorylation were also verified in
H1299 cells.
Conclusions: Red wine inhibits proliferation of lung cancer cells and blocks clonogenic survival at low concentrations.
This is associated with inhibition of basal and EGF-stimulated Akt and Erk signals and enhancement of total and
phosphorylated levels of p53. White wine mediates similar effects albeit at higher concentrations. Our data suggest
that wine may have considerable anti-tumour and chemoprevention properties in lung cancer and
deserves further systematic investigation in animal models of lung cancer.
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Cancer cells are characterized by accelerated proliferative
capacity and resistance to apoptosis (programmed cell
death). Non-small cell lung cancer (NSCLC) accounts
for 85% of lung cancer cases and despite utilization
of aggressive radio- and/or chemotherapy, fewer than
20% of such patients reach a 5 year survival [1]. This is due
to significant resistance of NSCLC to such conventional
cytotoxic therapies. Therefore, there is an urgent need to* Correspondence: ltsiani@brocku.ca
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reproduction in any medium, provided the oridentify new effective prevention strategies and therapies
for NSCLC.
Molecular signaling pathways of growth factor receptors,
such as the Epidermal Growth Factor (EGF) Receptor
(EGFR), stimulate cancer cell growth, survival and resistance
to cytotoxic therapy. Binding of EGF activates EGFR
and initiates signal transduction pathways, including
the phosphatidylinositol 3-kinase (PI3K)-Akt and Ras-Erk,
resulting in cell proliferation and survival [2]. Increased
EGFR signaling is linked to cancer and abnormal EGFR
expression is found in approximately 80% of cases of
NSCLC [2]. Although EGFR tyrosine kinase inhibitors
such as gefitinib and erlotinib provide a therapeuticLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Barron et al. Cancer Cell International 2014, 14:6 Page 2 of 13
http://www.cancerci.com/content/14/1/6benefit in treating patients with NSCLC, particularly
those with EGFR mutations, most patients eventually
develop resistance to such targeted therapies [2,3].
Activation of PI3K by EGFR generates 3-phosphoinositides
which bind and activate phosphoinositide-dependent
kinase-1(PDK-1). PDK-1 phosphorylates and activates the
serine threonine kinase Akt (protein kinase B (PKB)) [4,5].
Activated Akt in turn phosphorylates tuberous sclerosis
complex 2 (TSC2) leading to activation of the mammalian
target of rapamycin (mTOR) and p70 S6 kinase, resulting
in stimulation of protein synthesis, growth and proliferation
[4,5]. Activated Akt also phosphorylates Bad, a proapoptotic
Bcl-2 family member, causing its degradation resulting in
inhibition of apoptosis [4,5]. Akt is a proto-oncogene and
activated Akt leads to cancer cell proliferation, survival, and
resistance to chemo and radio-therapy [4-6]. Several studies
have shown that Akt is overexpressed in various cancer cell
lines and human malignancies [5,6]. Increased Akt
phosphorylation, a marker of activation of this molecule
[4], is seen in many cancer cells [5-8]. On the other hand,
targeting/inhibiting the Akt signaling pathway inhibits
cancer cell growth and enhances apoptosis [5,6].
The extracellular signal-regulated kinase (Erk) is a mem-
ber of the mitogen-activated protein kinase (MAPK) family,
shown to be up-regulated and involved in cell proliferation
and survival in various cancer cells [9].
The tumour suppressor p53 pathway is frequently inacti-
vated in cancer cells and both chemotherapy and radiother-
apy resistance has been strongly associated with reduced
p53 function [10]. Cytotoxic anti-cancer therapies induce
DNA-damage and/or -stress and activate signaling cas-
cades including the p53 pathway. This leads to inhibition
of cancer cell proliferation and induction of apoptosis. In
response to stress/DNA damage, p53 is phosphorylated
on multiple serine residues, including Ser 15, resulting
in inhibition of degradation and increased p53 levels.
Phosphorylated/activated p53 binds to downstream targets
leading to cell cycle arrest and/or apoptosis, both detrimental
to the uncontrolled growth of cancer cells [10].
Moderate consumption of red wine has been established
to have cardiovascular benefits [11]. A limited number of
in vitro studies using cancer cells [12-14], and some
epidemiological studies [11], indicate that red wine
possesses anti-cancer properties. Red wine is a rich
source of the polyphenol resveratrol which has been shown
to inhibit cancer cell proliferation, induce apoptosis [15,16],
and in a recent study by our group found to sensitize
prostate cancer cells to radiotherapy [17]. Although
many studies examined the effects of resveratrol on
cancer cell proliferation, investigations into the effect
of whole wine are limited. Interestingly, high intake
of beer or spirits is associated with increased risk of
lung cancer, while red wine intake is associated with
a reduced risk [18,19]. Studies indicate that regular andmoderate red wine consumption could have beneficial
health effects [20] and is associated with a 22% decrease
in risk of cancer [21].
In vitro studies have shown inhibition of growth of
human oral squamous carcinoma (SCC-25) cells [12],
and human prostate cancer cells [14] by red wine. In
addition, studies using red wine polyphenol extracts
found inhibition of breast cancer [22], colon carcinoma
[23], and skin epidermal [24] cells.
In the present study we found a significant inhibition
of human lung cancer cell proliferation and survival,
inhibition of Akt and Erk and induction of p53 by wine.
Results
Red wine inhibits proliferation and survival of A549 lung
cancer cells
The physicochemical composition of the four red wines
used in this study (W1-4) is shown in Table 1. There were
no significant differences in the basic physicochemical
composition of the wines with the exception that the
phenolic content of Pinot Noir (W2) was higher than
that of the other wines used. Sub-confluent, 24 hour
serum-deprived A549 lung cancer cells were incubated in
media containing 0.02, 0.2, 0.5, 2, or 5% red wine for 24
hours. All red wines used in the study inhibited thymidine
incorporation into cells in a dose-dependent manner
(Figure 1A).
Red wine contains the polyphenol resveratrol which is
known to have anti-proliferative effects [16,25]. The
resveratrol levels of the wines used in our study were
not measured but based on the literature [11] the
average concentration of resveratrol in red wine
ranges from 1-5 mg/L. Assuming that the resveratrol
(MW:228.24 g/mol) concentration in our wine was 5 mg/L
it is calculated that at the highest wine concentration
(5%) used in our study, the cells would have been exposed
to 1.1 μM resveratrol and therefore we used this concen-
tration of resveratrol and examined cell proliferation.
Figure 1B shows that A549 cell proliferation was signifi-
cantly inhibited by 5% red wine (W1: 45.85 ± 2.44,
W2: 23.54 ± 6.09, W3: 58.10 ± 21.11, and W4: 45.32 ± 6.54%
of untreated control) while no significant effect on cell pro-
liferation were seen with 1.1 μM resveratrol (97.33 ± 9.97%
of control). Interestingly, the combination of 1.1 μM
resveratrol and wine (44.06 ± 4.65% of control) inhibited cell
proliferation to the same level as wine alone. The ethanol
content of the wines used in our study was between 10.28
and 12.81% with an average of 11.59% (Table 1). Thymidine
incorporation in cells treated with ethanol, to match the
ethanol in 5% wine-treated cells, was not different than
control cells (100.03 ± 1.73% of control) (Figure 1B). Apart
from resveratrol, red wine contains other polyphenols
including quercetin, catechin and epicatechin all of which
have been shown to inhibit cancer cell proliferation at
Table 1 Basic physicochemical composition and phenolic content of wines
Wine Viscosity Residual sugar Titratable acidity Ethanol Glycerol pH Total phenolics
(centistrokes/min) (g/l) (g/l) (%v/v) (g/l) (mg/L gallic acid equivalents)
Cabernet Sauvignon
1.68 2.75 7.37 11.36 7.58 3.26 1868.3
Late harvest 2001 (W1)
Pinot Noir
1.65 4.12 7.02 11.91 5.54 3.43 2681.3*
2001 (W2)
Cabernet Franc
1.69 3.62 8.30 12.81 6.64 3.16 1378.8
2001 (W3)
Cabernet Sauvignon
1.58 5.75 8.17 10.28 5.35 3.15 1641.3
Early harvest 2001 (W4)
Data represent the average values of duplicate measurements of wine samples. *P < 0.05.
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the effect of red wine with that of 50 μM of each polyphenol
we saw inhibition of cancer cell proliferation by red wine
(23.54 ± 6.09) to levels similar with that achieved with 50 μM
of each polyphenol (21.9 ± 3.7, 32.3 ± 2.35, 38.23 ± 2.13,Th
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Figure 1 Effect of red wine on thymidine incorporation in A549 NSCLC
(A) the indicated wine concentrations, (B) without (control) or with 5% wine
the cells exposed to 5% wine), (C) without (control) or with 5% wine or 50 μM
or with 5% wine, 1 mM metformin or 25 nM rapamycin for 24 h at 37°C. Cells
indicated in the Methods. The results are the mean ± SE of 4 independent ex
*P < 0.05, **P < 0.01 vs. control.33.26 ± 6.11% of control for quercetin, catechin, epicatechin
and resveratrol, respectively) (Figure 1C).
We also compared the effect of red wine with that of the
mTOR inhibitor rapamycin [5,27] and the anti-diabetic
drug metformin [28], both of which inhibit signaling eventsTh
ym
id
in
e 
In
co
rp
or
at
io
n 
(%
 
o
f C
on
tro
l)
B
Th
ym
id
in
e 
In
co
rp
or
at
io
n 
(%
 
o
f C
on
tro
l)
D
cells. A549 cells were deprived of serum for 24 h then incubated with
or 1.1 μM resveratrol or ethanol (to match the ethanol concentration in
of quercetin, catechin, epicatechin or resveratrol, (D) without (control)
were washed and [3H]thymidine incorporation was measured as
periments performed in triplicate and expressed as percent of control.
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ing therapeutics in cancer. Exposure of A549 cells to 1 mM
metformin or 25 nM rapamycin resulted in a significant
inhibition of cell proliferation (28 ±5.7, 18.1 ± 4.1% of
control for metformin and rapamycin, respectively) that was
at a similar level to that achieved with red wine (Figure 1D).
We next examined the effect of red wine on clonogenic
cell survival. Exposure of the cells to 0.02 and 0.5% of two
red wines (Wine 2 and 3) resulted in a significant
inhibition of clonogenic cell survival while 2% red
wine abolished most of the ability of cells to create
surviving colonies (residual colony formation was W2:
4.5 ±0.38, W3: 8.21 ± 5.8% of control) (Figure 2). Exposure
of the cells to 4 nM and 400 nM resveratrol, to match the
resveratrol levels in cells exposed to 0.02% and 2% wine,
respectively, caused minor, non-significant, inhibition of
cell survival but exposure to 50 μM resveratrol did
inhibit clonogenic survival (7.8 ± 3.29) to levels close
to those achieved by 2% of wines 2 and 3 (Figure 2).
Similarly, exposure of the cells to ethanol, to match
the ethanol levels in cells treated with 2% wine, did
not have a significant effect on cell survival (Figure 2).
These results indicate that red wine induces a signifi-
cant inhibition of lung cancer cell survival that cannot be
explained by either the content of resveratrol or ethanol in
the wine.
Effect of red wine on glucose transport
Resveratrol has been suggested to directly inhibit glucose
uptake in cancer cells [29] and it has been previouslyFigure 2 Effect of red wine on survival of A549 cells. Cells were incuba
ethanol (to match the ethanol in 2% wine-treated cells) for 7 days followed b
were counted. Results are expressed as the surviving fraction compared to unshown that caloric restriction using a non-metabolizable
glucose analogue inhibits cell proliferation [30]. Therefore,
it was possible that the observed effects of red wine in the
present study were due to inhibition of glucose uptake.
For that, we examined the effect of wine on glucose
uptake in A549 cells. None of the red wines used in this
study significantly affected glucose uptake by A549 cells
(W1: 105.52 ± 6.35, W2: 83.47 ± 3.41, W3: 101.16 ± 6.81,
W4: 110.21 ± 12.29% of control) (Figure 3) suggesting
that the ability of red wine to inhibit cancer cell
proliferation is not dependant on modulation of glucose
uptake.
Red wine inhibits Akt and Erk phosphorylation/activation
Untreated A549 cells were found to have high levels of Akt
Thr308 phosphorylation (which mediates the activation of
this enzyme) and treatment with red wine was found to
significantly inhibit this elevated basal Akt phosphorylation.
Wines 1–3 were used in these experiments and all induced
greater than 60% inhibition of Akt Thr308 phosphorylation
(W1: 36.55 ± 6.7%, W2: 29.16 ± 4.07%, W3: 34.41 ± 7.59%
of control) (Figure 4A) without significantly affecting the
total levels of Akt (W1: 95.67 ± 3.18%, W2: 91.4 ± 4.28%,
W3: 87.90 ± 2.67% of control, Figure 4A).
Similarly, untreated A549 cells showed high levels of
basal Erk1/2 phosphorylation and red wine (Wines 1–3)
caused a marked inhibition of this activity reducing basal
Erk phosphorylation by more than 75% (W1:23.66 ±
5.9%, W2:20.94 ± 7.8%, W3: 19.20 ± 5.4%, of control,
Figure 4B) without affecting the total levels of this enzymeted with the indicated concentrations of red wine, resveratrol or
y fixing and staining with 0.05% methylene blue and colonies (> 50 cells)
treated control. RSV = Resveratrol, *P < 0.05, **P < 0.01 vs. control.
Figure 3 Effect of red wine on glucose uptake. Serum-deprived A549 cells (24 h) were treated without (control) or with 5% red wine, or ethanol
vehicle control for an additional 24 h at 37°C. Cells were washed and [3H]-2 deoxy-glucose uptake was measured as discussed in the Methods. The
results are the mean ± SE of 5 independent experiments performed in triplicate and expressed as a percent of control.
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control, Figure 4B).
We also examined the effect of red wine on EGF-
stimulated Akt and Erk1/2 phosphorylation. Exposure of
the cells to 100 ng/ml EGF caused a rapid (within 10 min)
and significant enhancement of Akt phosphorylation (EGF:
193.46 ± 23.98 compared to control, Figure 4C). Import-
antly, red wine (Wines 1–3) abolished both the basal and
the EGF-stimulated Akt phosphorylation (W1+ EGF:
49.01 ± 11.32, W2+ EGF: 59.43 ± 8.1, W3+ EGF: 57.89 ±
3.43% of control, Figure 4C). Similarly, EGF induced a
greater than 5-fold increase in Erk phosphorylation and red
wine (1–3) abolished both basal and EGF-stimulated Erk
phosphorylation (EGF: 538 ± 97, W1 + EGF: 25.16 ± 4.29,
W2 + EGF: 31.98 ± 13.86, W3 + EGF: 28.06 ± 12.36% of
control, Figure 4D).
Red wine increases p53 levels
Red wine increased total p53 levels by 2–4 fold
(W1: 272.07 ± 52.5, W2: 419.3 ± 62.51, W3:399.72 ± 38.56%
of control, Figure 5). Similarly, the levels of Ser15 p53
phosphorylation were increased by 2–4 fold (W1: 206 ± 34,
W2: 283 ± 99, W3:467 ± 32% of control) in response to red
wine treatment (Figure 5).
White wine inhibits survival of A549 cells and reduces Akt
phosphorylation levels
To examine whether the anti-proliferative and signaling
effects of wine were specific to red wine, we examined the
effects of the white wine Riesling (produced in CCOVI,
2013). Total phenolic content of Riesling was measuredand found to be (3.41 mg/L gallic acid equivalents) which
is lower than the concentrations found in the red wines.
The other basic physicochemical composition of white
wine including pH and ethanol content were not different
from the red wines used. Exposure of cells to 0.02, 0.5, 1
and 2% white wine also resulted in a dose-dependent
inhibition of cell survival (Figure 6). A significant inhibition
of cell survival was seen with 0.5% white wine, while
at 2%, the inhibition of clonogenic survival (5% of control)
was comparable to that seen with red wine. White
wine contains lower levels of resveratrol (0.5-0.8 mg/ml)
compared to red wine. When cells were exposed to 3.24
nM resveratrol to match the resveratrol levels in cells
exposed to 2% white wine, cell survival was not affected.
Similar results were observed when cells were exposed to
ethanol to match the ethanol in cells treated with 2%
white wine (Figure 6).
To examine the effects of white wine on cellular signaling
events, we analyzed its effects on Akt phosphorylation.
Exposure of A549 cells to 2% and 5% white wine resulted
in inhibition of basal Akt phosphorylation (67% and 59% of
control respectively), while total Akt levels were not
affected (Figure 7).
Inhibition of Akt phosphorylation by wine in H1299 cells
Finally, to ensure that the effects of red and white wine
on modulation of survival signals in lung cancer cells
were not unique to A549 cells we analyzed total and
phosphorylated Akt levels in another adenocarcinoma
NSCLC cell model, the H1299 cells. Exposure of H1299
cells to 2% red wine (W2, Pinot Noir) (Figure 8A),
Akt
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Figure 4 Effect of red wine on Akt and ERK. Total cell lysates were prepared from A549 cells that were serum-deprived for 24 h then treated
with or without 5% wine for 24 h. Stimulation with 100 ng/ml EGF was performed for 10 min before cell lysis (C, D). Cell lysates (20 μg) were
resolved by SDS-PAGE and immunoblotted with anti-phospho, or anti-total- Akt antibody (A, C) or anti-phospho, or anti-total- Erk antibody
(B, D). Representative immunoblots of 3 independent experiments are shown. Immunoblots were scanned to quantitate the density of the bands
and the results in the bar graphs are the mean ± SE of 3 independent experiments. All values are arbitrary densitometry units expressed relative
to untreated control. *P < 0.05, **P < 0.01 vs. control, #p < 0.05 vs. EGF.
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control), while the inhibition seen with 5% white wine
(Riesling), (Figure 8B) was lower (60% of control). Total
Akt levels were not affected by either red or white wine
treatment (Figure 8A and B).Discussion
In contrast to the well-documented inverse relationship
between moderate wine consumption and cardiovascular
disease [11], and although limited evidence indicates that
wine can inhibit cancer cell proliferation [12,13], the
p53
p-p53(Ser15)
Figure 5 Effect of red wine on p53. Serum-deprived (24 h) A549 cells were treated with or without 5% red wine for 24 h. Total cell lysates were
prepared and 20 μg of protein from each sample were resolved by SDS-PAGE and immunoblotted with anti-phospho, or anti-total- p53 antibody.
A representative immunoblot is shown. Immunoblots were scanned to quantitate the density of the bands and the results in the bar graphs are
the mean ± SE of 3 independent experiments. All values are arbitrary densitometry units expressed relative to untreated control.
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established. Epidemiological evidence has revealed that
while alcoholic beverages such as beer increase the
risk for lung cancer, moderate consumption of wine
is protective [18,19].
The three main subtypes of NSCLC, squamous cell
lung carcinoma, adenocarcinoma and large cell lung
carcinoma, account for the majority of lung cancer cases
and are associated with poor prognosis [1]. In particular,
NSCLC adenocarcinoma is diagnosed with increased
frequency in both smokers and non-smokers with very
poor overall treatment outcome despite aggressive
cytotoxic therapies. For this reason we focused the
present study on NSCLC adenocarcinoma. We found
that red wine significantly inhibited proliferation of A549
human lung adenocarcinoma cells. All red wines exam-
ined here exhibited anti-proliferative effects, irrespective
of variety and harvest time. Pinot Noir (Wine 2), a red
wine with the highest phenolic content, caused the greatest
inhibition of proliferation (Figure 1B) but its effect was not
statistically different from the other red wines used. We
used clonogenic survival assays in our studies becausethese experiments demonstrate the ability of cancer cells,
not only to proliferate but to also develop surviving
colonies that continue to grow and could develop new
tumors in an in vivo setting. For that clonogenic assays
are highly useful evaluators of both tumor growth and
oncogenic potential. We observed a potent ability of red
wines to induce a statistically significant inhibition of
clonogenic survival at low concentration (0.02%) (Figure 2).
At this concentration, white wine did not produce a
statistically significant inhibition of clonogenic survival
(Figure 6). A 25-fold increase in the concentration of red
wines (from 0.02 to 0.5%) did not inhibit clonogenic
survival further, than the one achieved by 0.02%, but
this increase in concentration of white wine showed a
significant inhibition of clonogenic survival (Figure 6).
At high concentrations (2%) both red and white wines
were able to abolish the majority of the capacity of
lung cancer cells for clonogenic survival (Figures 2
and 6). These results demonstrate that although both
red and white wines are able to inhibit lung cancer
cell growth and oncogenic potential there is a difference
in their potency. Our results are consistent with those of
**
**
**
Figure 6 Effects of white wine on clonogenic survival of A549 cells. Cells were incubated with the indicated concentrations of white wine
(Riesling), resveratrol or ethanol (to match the concentrations found in 2% white wine-treated cells) for 7 days followed by fixing and staining
with 0.05% methylene blue and colonies (>50 cells) were counted. Results are expressed as the surviving fraction compared to untreated control
of 3–5 individual experiments. RSV = resveratrol, **P < 0.01 vs. control.
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at concentrations similar to those used here, inhibited
proliferation of human oral squamous carcinoma (SCC-25)
cells. Similarly, red wine inhibited the proliferation of
human prostate cancer cells [14]. Wallenborg et al. [13]
observed A549 and other lung, colon and cervical cancer
cell death with red wine (Raimat) at concentrations of 2.5
and 5%. However, in contrast to our observations they
detected only minor, non-statistically significant, inhibition
of lung cancer cells with 5% white wine (Chardonnay) and
no inhibition of survival of colon and cervical cancer cells
[13]. This study [13] did not examine the effects of red or
white wine on cancer cell clonogenic potential.
Polyphenols are believed to mediate many of the health
benefits of moderate wine consumption. Studies using red
wine polyphenol extracts showed an inhibition of MCF-7
breast cancer cells [22], colon carcinoma [23], and mouse
skin epidermal cells [24]. Earlier, we observed significant
inhibition of prostate cancer cell clonogenic survival
and radio-sensitization after treatment with 2.5-10 μM
resveratrol [17]. In the present study resveratrol (1.1 μM)
and ethanol matching the expected concentrations in red
wine did not inhibit proliferation of A549 lung cancer cells
indicating that resveratrol or ethanol alone do not mediate
the effects of red wine in lung cancer cells. The lack of
additivity or synergism between resveratrol 1.1 μM and
red wine indicates that components already present in
wine are sufficient to induce a significant inhibition of cell
proliferation and survival. These observations are consistentwith the results of Wallenborg et al. [13] who could not
demonstrate a role of resveratrol in the red wine-mediated
inhibition of cancer cell death [13]. It is possible that the
total phenolic content, which is much higher in red wine
(1378–2681 mg/L gallic acid equivalents) compared to
white wine (3.41 mg/L gallic acid equivalents for Riesling
wine used in this study), is involved in the overall
anti-tumor action of wine. We suggest that future
studies should investigate the effects of combined, clinically
achievable, doses of polyphenols, such as quercetin,
epicatechin and resveratrol, that we utilized in the present
study, which as single agents do exhibit anti-tumor effects
in high concentrations (Figure 1C).
The pigment content of red wine was suggested to be
responsible for its cellular action. Wallenborg et al. [13]
observed a correlation between pigment content, mea-
sured as absorbance at 520 nm wavelength, the inhibition
of thioredoxin reductase (TrxR) and the cellular effects of
different wines. Although wine pigment may contribute to
the anti-proliferative effects of wine, the data obtained in
our study do not offer strong support to this notion. Red
wine did inhibit clonogenic survival significantly at low
concentrations (0.02%) but at higher concentrations both
red and white wine affected clonogenic survival to a
similar extent (Figures 2 and 6).
It should be noted that in addition to polyphenols,
wine also contains ethyl carbamate (10-15 ng/g) which is
formed during fermentation. The metabolite vinyl carbamate
has been previously reported to increase lung and intestinal
p-Akt (Thr308)
Akt
Figure 7 Effect of white wine on Akt in A549 NSCLC cells. Total cell
lysates were prepared from A549 cells that were serum-deprived for 24 h
then treated with or without 2% or 5% white wine (Riesling) for 24 h. Cell
lysates (25 μg) were resolved by SDS-PAGE and immunoblotted with
anti-phospho or anti-total- Akt antibody. Representative immunoblots of
2 independent experiments are shown. Immunoblots were scanned to
quantitate the density of the bands and the results in the bar graphs are
mean ± SE. All values are arbitrary densitometry units expressed relative
to untreated control.
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[31]. Consumption of one glass of wine will result in
an approximate total intake of 2.5-3.7 μg ethyl carbamate.
This is a dose of 41–61 ng/kg (for a 60 kg human), which is
approximately 1 million times less than the mutagenicity-
inducing dose of vinyl carbamate used in the study by
Hernadez et al. [31] and therefore may not cause any
adverse health effects. However the presence of ethyl
carbamate in wine must be acknowledged and future
wine studies should explore this issue.
A number of groups, including our own [32], observed
highly activated EGFR, Akt and Erk signaling pathways
in human NSCLC tumours [8]. Importantly, the level of
phosphorylation and activity of EGFR appears to correlate
negatively with survival in lung cancer patients [8]. Overex-
pression of phospho-Akt in NSCLC tissue, has been found
to be correlated with poor prognosis [7]. Brognard et al. [6]
found phosphorylated Akt in 16 out of 19 NSCLC cell lines
tested, indicating that Akt is constitutively active in NSCLC.A549 cells harbor an activating K-Ras mutation and highly
activated K-Ras-PI3K pathways [33]. We observed high
levels of Akt phosphorylation in these cells consistently,
despite serum deprivation (Figure 4). Red wine caused a
marked inhibition of basal Akt phosphorylation in both
A549 (Figure 4) and H1299 (Figure 8) lung cancer cells.
White wine, although not as potent in terms of inhibiting
clonogenic survival, also inhibited Akt phosphorylation in
both A549 (Figure 6) and H1299 (Figure 8) cells. These
findings are important and indicate that wine is capable of
inhibiting the activity of this kinase and this may relate to
the inhibition of NSCLC cell growth. In agreement with
our data, red wine has been shown to inhibit phosphoryl-
ation of Akt in vascular smooth muscle cells [34]. Although
no other studies examined the effect of wine on Akt
in cancer cells, we observed inhibition of basal Akt
phosphorylation with 2.5 and 5 μM resveratrol in human
PC3 and 22RV1 prostate cancer cells [17] and other
studies in breast [35] and uterine [36] cancer cells showed
similar results with 100 μM resveratrol.
The present study is the first to show a significant
inhibition of Erk by red wine. Our data are in agreement
with other studies showing a significant inhibition of
Erk phosphorylation in human fibrosarcoma cells by
resveratrol [24] and blockage of Erk phosphorylation,
inhibition of the upstream kinases Raf and MEK, and
suppression of the EGF or Ras-induced transformation of
JB6Pt mouse skin epidermal cells by red wine extract [24].
A549 cells express wild type p53 and the present study
is the first to show induction of p53 by red wine. In
addition to total p53, phosphorylated p53 was increased
indicating enhanced activity of this tumour suppressor.
Other studies have shown increased p53 levels in response
to resveratrol treatment. In thyroid [37], breast [38-41],
colon [42] and prostate [17,43,44] cancer cells resveratrol
significantly increased p53 levels. The increase in p53
levels seen by red wine in our study is comparable to that
seen by 25 μM resveratrol in lung cancer cells [45]. In vivo
studies have shown that red wine polyphenols reduced
tumor growth in mice grafted with colon cancer cells and
reduced the development of colon carcinomas, an effect
that was associated with increased p53 expression [46].
p53 phosphorylation at Ser 15 leads to reduced interaction
of p53 with its negative regulator MDM2, a ubiquitin
ligase which targets p53 for ubiquitination and proteoso-
mal degradation [47], resulting in increased p53 levels. On
the other hand, activated Akt leads to phosphorylation of
MDM2 leading to its translocation to the nucleus and
inhibition of p53. It is possible that the increased p53
levels by red wine in the present study could be explained
by inhibition of Akt activity on MDM2.
An important finding in the present study is the inhib-
ition of EGF-stimulated Akt and Erk phosphorylation by
red wine. High levels of expression and activation of EGFR
p-Akt (Thr308)
Akt
A B
p-Akt (Thr308)
Akt
Figure 8 Effect of wine on Akt in H1299 NSCLC cells. Total cell lysates were prepared from H1299 cells that were serum-deprived for 24 h
then treated with or without 2% red wine (Pinot Noir) (A) or 5% white wine (Riesling) (B) for 24 h. Cell lysates (25 μg) were resolved by SDS-PAGE and
immunoblotted with anti-phospho or anti-total- Akt antibody. Representative immunoblots are shown. Immunoblots were scanned to quantitate the
density of the bands. All values are arbitrary densitometry units expressed relative to untreated control.
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mented that a large number of NSCLCs overexpress EGFR
[2,32]. Furthermore, activating EGFR mutations are very
frequent in NSCLC adenocarcinomas and are the target of
modern therapy with EGFR inhibitors [48]. Treatment of
A549 cells with the tyrosine kinase inhibitor gefitinib, used
clinically, inhibits EGF-stimulated Akt phosphorylation
[49]. In the present study we detected that wine can effect-
ively suppress Akt phosphorylation in A549 and H1299
lung cancer cells (Figures 7 and 8) similar to clinically used
EGFR inhibitors such as gefitinib.
Activated Akt leads to activation of the Ser/Thr kinases
mTOR and p70 S6K involved in protein synthesis and pro-
liferation [4,5,27]. It is well established that the mTOR- p70
S6K cascade is activated in many cancers and extensive
effort has been placed on targeting this cascade in an
attempt to inhibit cancer cell proliferation, tumorigenesis
and metastasis [5,27]. Inhibitors of mTOR such as rapamycin
and rapamycin derivatives [5,27] have been developed
and are currently in clinical use or clinical trials. On
the other hand, the biguanine and widely used anti-diabetic
drug metformin can also inhibit the mTOR pathway and is
actively investigated in cancer [28]. We have compared theeffects of rapamycin and metformin with those of red wine
on A549 cells and observed comparable inhibition of cell
proliferation, indicating that wine may indeed deserve equal
attention compared to other therapeutics currently studied
against cancer.Conclusions
The work presented here shows that low doses of wine
potently inhibit proliferation and clonogenic survival of
human lung cancer cells through a mechanism that is
independent of resveratrol and ethanol. Although both
red and white wines demonstrated significant inhibition
of cancer cell survival at high doses, red wine shows
more potent anti-tumor activity compared to white. Wine
inhibits basal Akt and Erk phosphorylation/activation,
induces the tumor suppressor p53 and abolishes the
phosphorylation of Akt and Erk by EGF. These results
suggest that wine may have anti-cancer and chemo-
preventive properties. Future studies need to investigate
systematically the anti-tumor effects of wine in in-vivo
models of lung cancer and analyze in detail the molecular
mechanism of its action.
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Materials
Human A549 and H1299 NSCLC cells were purchased
from American Type Culture Collection (ATCC). Cell
culture (RPMI) media, fetal bovine serum (FBS), trypsin,
and antibiotic were from GIBCO (Burlington, ON, Canada).
Total and phospho-specific Akt, Erk and p53 antibodies
were purchased from New England Biolabs (Mississauga,
ON, Canada). [3H]thymidine and [3H]2-deoxy-D-glucose
were from PerkinElmer (Boston, MA). Metformin, rapamy-
cin, resveratrol, quercetin, catechin, epicatechin, bovine
serum albumin and other chemicals were purchased from
Sigma (Oakville, ON). Red and white wine was prepared by
Dr Pickering at the Cool Climate Oenology and Viticulture
Institute (CCOVI), Brock University. The grapes used
were from vineyards in Niagara-On-The-Lake, Ontario. The
basic physicochemical composition and phenolic content
of the wines were measured as previously described [50,51].
Cell culture and treatment
A549 and H1299 cells were grown in RPMI media
containing 5 mM glucose, 10% (v/v) FBS, and 1% (v/v)
antibiotic-antimycotic solution (100 U/ml penicillin,
100 μg/ml streptomycin, and 250 ng/ml amphotericin B)
in a humidified atmosphere of 5% CO2– 95% air at 37°C.
The final concentration and the time of incubation with
wine or other agents are indicated in each figure. Where
indicated the cells were stimulated with 100 ng/ml EGF
for 10 min.
Thymidine incorporation
Subconfluent A549 cells were serum-deprived for 24 hours
and then treated with the indicated concentrations of wine
(added to media) for 12 hours followed by addition of
10 μM [3H]thymidine for an additional 12 hours. At the
end of the treatment, the media was removed, the
cells were rinsed with ice-cold HEPES-buffered saline
(HBS; 140 mM NaCl, 5 mM KCl, 20 mM HEPES, 2.5 mM
MgSO4, and 1 mM CaCl2, pH 7.4) and subsequently, the
unincorporated [3H]thymidine was precipitated out of the
cells with 10% trichloro- acetic acid (TCA) for 10 minutes
at 4°C. The TCA was aspirated and the cells were rinsed
twice with ice-cold HBS, followed by solubilization with
0.05 N NaOH and radioactivity counting. Cellular protein
content was measured using the BioRad Protein Assay.
Clonogenic assays
Clonogenic assays were performed as described previously
[17]. Cells (500–1000) were seeded in triplicates, allowed
to adhere overnight and were incubated with media
containing the indicated concentrations of red wine,
resveratrol, or ethanol (to match the ethanol in wine-
treated cells) for 7 days. Cells were then fixed and stained
with 0.05% methylene blue and colonies (> 50 cells) werecounted. Results are expressed as the surviving fraction
compared to untreated control.
2-Deoxy-D-glucose uptake
Glucose uptake measurements were carried out in HBS
containing 10 μM 2-[3H]-Deoxy-D-glucose as previously
described [52]. The uptake assay was terminated by
washing the cells with ice-cold 0.9% NaCl, followed by
cell solubilization with 0.05 N NaOH and radioactivity
counting.
Immunoblotting
After treatment, cell lysates were prepared followed by
separation of 20 μg of protein sample by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoblotting with the indicated antibodies as
described earlier [53]. Densitometric analysis was performed
using Image J software.
Statistical analysis
The results are the Mean ± SEM of the indicated number of
independent experiments. Analysis of variance (ANOVA)
or student’s paired t-test was used. Statistical significance
was assumed at P < 0.05. SPSS v19.0 was used.
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